Why is Aclaris Therapeutics Stock Trading Lower on Monday?
Aclaris Therapeutics misses Phase 2 bosakitug endpoints but launches its Phase 2b modzatinib trial for moderate-to-severe lichen planus.

Last updated: 2026-11-16 19:00:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Aclaris Therapeutics, Inc. (ACRS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.56, with a market capitalization of $621.76M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.34 to $6.60. This page covers its latest market performance, valuation, price trends and company information.
$621.76M | |
$3.38 | |
$3.80 | |
$3.13 | |
$3.92 | |
7.13M | |
2.93M | |
-- | |
$6.60 | |
$2.34 | |
-- | |
-- |
Aclaris Therapeutics, Inc. (ACRS) is currently trading at $3.56 as of 2026-11-16 18:57:00, down 9.69% ($0.38) from the previous close of $3.92
During today's regular trading session, ACRS has traded between $3.13 and $3.80, with a trading volume of 7.13M shares. The current price is near the middle of today's range.
ACRS is down 1.66% during regular trading hours.
Over the past seven days, Aclaris Therapeutics, Inc. (ACRS) moved from $3.61 to $3.56, representing a decline of 1.52% ($0.05).
The stock traded between $3.13 and $4.40 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 2.05 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 28.5%
ACRS is currently trading at $3.56, placing it 28.5% of the way from its 52-week low of $2.34 to its 52-week high of $6.60. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 73 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Aclaris Therapeutics, Inc. and ACRS stock.
Aclaris Therapeutics misses Phase 2 bosakitug endpoints but launches its Phase 2b modzatinib trial for moderate-to-severe lichen planus.
U.S. stock futures fell as Aclaris plunged 21% after its dermatitis trial failed; Summit and other stocks also dropped in premarket trading.
Take-Two rose 4% ahead of GTA VI’s Nov. 19 release on strong presales. GreenPower led gainers, while Datavault AI plunged 43%.
- Dual Inhibition of ITK and JAK3 Provides Potential for Modzatinib to be the First Mechanistically Complete Oral Therapy for Lichen Planus, an Unaddressed Inflammatory Disease with No Approved Therapeutic Options --
- The ADMIRATION Trial Did Not Achieve its Primary Endpoint of Percent Change in Eczema Area and Severity Index (EASI) Score from Baseline at Week 24 -- Aclaris Remains Focused on Prioritizing the Development of its
Eligible investors can buy real shares of Aclaris Therapeutics, Inc. (ACRS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ACRS, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ACRS shares and USD.
ACRS Shares to USD
1.00 ACRS shares = 3.555 USD
Calculations are estimates based on the latest available price and are for reference only.